Trackforce and Scylla Partner to Connect AI Detection, Guard Dispatch & Incident Resolution
The security industry historically struggles with siloed systems, creating gaps between threat identification and immediate physical response. As security providers modernize their operations, this integration tackles two critical challenges: reducing the high rate of false-positive alerts that drain resources and improving situational awareness for guards responding to incidents. By filtering out non-critical events before dispatch and equipping responders with AI-verified incident details, the partnership helps security teams allocate personnel more effectively, respond faster to real threats, and enhance the safety and preparedness of guards in the field.
'This is a direct response to what our customers have been asking for,' said Byron McDuffee, CEO of Trackforce. 'With labor shortages and high false-positive rates straining security teams, this partnership gives our clients a smarter way to deploy their skilled guards more efficiently. By embedding Scylla's AI into our workflows, we're helping customers boost situational awareness, speed up response times, and streamline administrative processes like billing, reporting, and accountability.'
The combined solution bridges Scylla's smart event detection capabilities with the newly launched TrackTik Command Center. Whether identifying an active shooter on a camera feed or detecting an intrusion at a critical infrastructure site via drones, verified incidents are instantly pushed into the TrackTik platform, triggering automated response protocols. This eliminates manual handoffs, reduces response times, and ensures complete visibility from detection through resolution.
'The security industry has been reactive for too long. Seeing threats but lacking the ability to respond quickly and effectively is more than an issue,' said Albert Stepanyan, founder and CEO of Scylla. 'Together with Trackforce, we're changing that dynamic by providing complete situational awareness and faster response coordination, helping security teams move from passive monitoring to proactive intervention.'
By fusing detection and response, this first-of-its-kind integration provides security service providers with a full closed-loop system, reducing risks, streamlining operations, and enabling new high-margin services like remote guarding and drone response. It is especially powerful for industries like data centers, energy, critical infrastructure, commercial real estate, high-net-worth residential, and automotive dealerships, where proactive threat detection and rapid incident resolution are critical to protecting investments and maintaining business continuity.
To learn more about Trackforce's operations and mission, visit www.trackforce.com
About Trackforce
Trackforce is dedicated to developing advanced solutions that enhance the efficiency and effectiveness of security operations worldwide. Its commitment to delivering innovative web and mobile technology solutions is unwavering, as it constantly seeks to empower security professionals and streamline their operational challenges. For additional information, please visit https://www.trackforce.com.
About Scylla
At Scylla, our mission is to create the best possible AI tech for video surveillance. As a technology-first company, we are committed to leveraging our expertise to deliver unparalleled precision and reliability in our solutions. We not only prioritize safety but also develop highly precise and sensitive AI solutions for video surveillance and security at large. We believe that through innovation and technology, we can provide our clients with the tools they need to protect what matters most and improve operations of their organizations. Learn more about Scylla at https://www.scylla.ai/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
HCA Healthcare Reports Second Quarter 2025 Results
Raises 2025 Guidance NASHVILLE, Tenn., July 25, 2025--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2025. Key second quarter metrics (all percentage changes compare 2Q 2025 to 2Q 2024 unless otherwise noted): Revenues increased 6.4 percent to $18.605 billion Net income attributable to HCA Healthcare, Inc. increased 13.1 percent to $1.653 billion Diluted earnings per share increased 23.5 percent to $6.83 per diluted share, and diluted earnings per share, as adjusted, increased 24.4 percent to $6.84 per diluted share Adjusted EBITDA increased 8.4 percent to $3.849 billion Cash flows from operating activities totaled $4.210 billion, compared to $1.971 billion in the second quarter of 2024 Same facility admissions increased 1.8 percent and same facility equivalent admissions increased 1.7 percent "We are pleased to report strong financial results for the second quarter. They reflected solid revenue growth, improved margins, and better outcomes for our patients. I want to thank our exceptional colleagues for their great work and continuous efforts to improve," said Sam Hazen, Chief Executive Officer of HCA Healthcare. Revenues in the second quarter of 2025 totaled $18.605 billion, compared to $17.492 billion in the second quarter of 2024. Net income attributable to HCA Healthcare, Inc. totaled $1.653 billion, or $6.83 per diluted share, compared to $1.461 billion, or $5.53 per diluted share, in the second quarter of 2024. Results for the second quarter of 2025 include losses on sales of facilities of $3 million, or $0.01 per diluted share, compared to gains on sales of facilities of $12 million, or $0.03 per diluted share, in the second quarter of 2024. For the second quarter of 2025, Adjusted EBITDA totaled $3.849 billion, compared to $3.550 billion in the second quarter of 2024. Diluted earnings per share, as adjusted, and Adjusted EBITDA are non-GAAP financial measures. A table providing supplemental information on these non-GAAP financial measures and reconciling GAAP measures of financial performance to them is included in this release. Same facility admissions increased 1.8 percent and same facility equivalent admissions increased 1.7 percent in the second quarter of 2025, compared to the prior year period. Same facility emergency room visits increased 1.3 percent in the second quarter of 2025, compared to the prior year period. Same facility inpatient surgeries declined 0.3 percent, and same facility outpatient surgeries declined 0.6 percent in the second quarter of 2025, compared to the same period of 2024. Same facility revenue per equivalent admission increased 4.0 percent in the second quarter of 2025, compared to the second quarter of 2024. Balance Sheet and Cash Flows from Operations As of June 30, 2025, HCA Healthcare, Inc.'s balance sheet reflected cash and cash equivalents of $939 million, total debt of $44.483 billion, and total assets of $59.536 billion. During the second quarter of 2025, capital expenditures totaled $1.176 billion, excluding acquisitions. Cash flows provided by operating activities in the second quarter of 2025 totaled $4.210 billion, compared to $1.971 billion in the second quarter of 2024. During the second quarter of 2025, the Company repurchased 7.031 million shares of its common stock at a cost of $2.505 billion. The Company had $5.753 billion remaining under its repurchase authorization as of June 30, 2025. As of June 30, 2025, the Company had $6.208 billion of availability under its credit facility (after giving effect to letters of credit and amounts reserved to backstop our commercial paper program). Dividend HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share on the Company's common stock. The dividend will be paid on September 30, 2025 to stockholders of record at the close of business on September 16, 2025. The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company's financial condition and results of operations. Future dividends are expected to be funded by cash balances and future cash flows from operations. 2025 Guidance Update Today, the Company is updating its 2025 estimated guidance ranges issued on January 24, 2025. Previous 2025 Guidance Range, as of January 24, 2025 Revised 2025 Guidance Range, as of July 25, 2025 Revenues $72.80 to $75.80 billion $74.00 to $76.00 billion Net Income Attributable to HCA Healthcare, Inc. $5.85 to $6.29 billion $6.11 to $6.48 billion Adjusted EBITDA $14.30 to $15.10 billion $14.70 to $15.30 billion EPS (diluted) $24.05 to $25.85 per diluted share $25.50 to $27.00 per diluted share Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 billion. The Company's guidance contains a number of assumptions, including, among others, the Company's current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payer mix, the ongoing impacts of the two major 2024 hurricanes, the impact of current and future health care public policy developments, as well as general business or economic conditions, including inflation, and the impact of trade policies, including tariffs, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets. Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release. The Company's guidance is based on current plans and expectations and are subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company's "Forward-Looking Statements." Earnings Conference Call HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company's Investor Relations web page at About the Company As of June 30, 2025, HCA operated 191 hospitals and approximately 2,500 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company's financial guidance for the year ending December 31, 2025, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan," "initiative" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic or business conditions nationally and regionally in our markets, including inflation, and the impact of trade policies, including changes in, or the imposition of, tariffs and/or trade barriers; changes in revenues resulting from declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, pharmaceuticals, supply chain or other expenditures; workforce disruptions; supply and pharmaceutical shortages and disruptions (including as a result of tariffs or geopolitical disruptions); and the impact of potential federal government shutdowns, holds on or cancellations of congressionally authorized spending and interruptions in the distribution of governmental funds, (2) the impact of current and future health care public policy developments and the implementation of new, and possible changes to existing, federal, state or local laws and regulations affecting the health care industry, including the expiration of enhanced premium tax credits ("EPTCs") for individuals eligible to purchase insurance coverage through federal and state-based health insurance marketplaces, changes in the structure and administration of, and funding for, federal and state agencies and programs, and effects of the One Big Beautiful Bill Act ("OBBBA"), (3) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and those that may be required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of OBBBA, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) the ability to achieve operating and financial targets, develop and execute resiliency plans to offset to the extent possible impacts from OBBBA, the scheduled expiration of EPTCs and tariffs, attain expected levels of patient volumes and revenues, and control the costs of providing services, (6) possible reductions or other changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs and state directed payment arrangements, any of which may negatively impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (7) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of actual and potential cybersecurity incidents or security breaches involving us or our vendors and other third parties, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, including Hurricanes Milton and Helene, physical risks from changing global weather patterns or similar events beyond our control on our assets and activities and the communities we serve, (24) changes in U.S. federal, state, or foreign tax laws, interpretations of tax laws by taxing authorities, other standard setting bodies or judicial decisions, (25) the results of our efforts to use technology and resilience initiatives, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to "Company," "HCA" and "HCA Healthcare" as used throughout this release refer to HCA Healthcare, Inc. and its affiliates. HCA Healthcare, Consolidated Comprehensive Income StatementsSecond QuarterUnaudited(Dollars in millions, except per share amounts) 2025 2024 Amount Ratio Amount Ratio Revenues $ 18,605 100.0 % $ 17,492 100.0 % Salaries and benefits 8,138 43.7 7,685 43.9 Supplies 2,844 15.3 2,634 15.1 Other operating expenses 3,793 20.4 3,623 20.7 Equity in earnings of affiliates (19 ) (0.1 ) — — Depreciation and amortization 863 4.7 819 4.7 Interest expense 568 3.0 506 2.9 Losses (gains) on sales of facilities 3 — (12 ) (0.1 ) 16,190 87.0 15,255 87.2 Income before income taxes 2,415 13.0 2,237 12.8 Provision for income taxes 524 2.8 550 3.2 Net income 1,891 10.2 1,687 9.6 Net income attributable to noncontrolling interests 238 1.3 226 1.2 Net income attributable to HCA Healthcare, Inc. $ 1,653 8.9 $ 1,461 8.4 Diluted earnings per share $ 6.83 $ 5.53 Shares used in computing diluted earnings per share (millions) 241.911 264.071 Comprehensive income attributable to HCA Healthcare, Inc. $ 1,701 $ 1,461 HCA Healthcare, Consolidated Comprehensive Income StatementsFor the Six Months Ended June 30, 2025 and 2024Unaudited(Dollars in millions, except per share amounts) 2025 2024 Amount Ratio Amount Ratio Revenues $ 36,926 100.0 % $ 34,831 100.0 % Salaries and benefits 16,135 43.7 15,392 44.2 Supplies 5,608 15.2 5,305 15.2 Other operating expenses 7,638 20.7 7,229 20.8 Equity in (earnings) losses of affiliates (37 ) (0.1 ) 2 — Depreciation and amortization 1,723 4.7 1,614 4.6 Interest expense 1,115 3.0 1,018 2.9 Losses (gains) on sales of facilities 2 — (213 ) (0.6 ) 32,184 87.2 30,347 87.1 Income before income taxes 4,742 12.8 4,484 12.9 Provision for income taxes 1,026 2.7 995 2.9 Net income 3,716 10.1 3,489 10.0 Net income attributable to noncontrolling interests 453 1.3 437 1.2 Net income attributable to HCA Healthcare, Inc. $ 3,263 8.8 $ 3,052 8.8 Diluted earnings per share $ 13.28 $ 11.47 Shares used in computing diluted earnings per share (millions) 245.654 266.044 Comprehensive income attributable to HCA Healthcare, Inc. $ 3,341 $ 3,044 HCA Healthcare, Consolidated Balance SheetsUnaudited(Dollars in millions) June 30, March 31, December 31, 2025 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 939 $ 1,060 $ 1,933 Accounts receivable 10,459 11,088 10,751 Inventories 1,792 1,794 1,738 Other 2,373 2,316 1,992 15,563 16,258 16,414 Property and equipment, at cost 64,388 63,680 62,514 Accumulated depreciation (34,265 ) (33,942 ) (33,100 ) 30,123 29,738 29,414 Investments of insurance subsidiaries 531 550 569 Investments in and advances to affiliates 654 657 662 Goodwill and other intangible assets 10,273 10,237 10,093 Right-of-use operating lease assets 2,156 2,132 2,131 Other 236 226 230 $ 59,536 $ 59,798 $ 59,513 LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities: Accounts payable $ 4,250 $ 4,488 $ 4,276 Accrued salaries 2,072 1,857 2,304 Other accrued expenses 4,513 3,767 3,899 Short-term borrowings and long-term debt due within one year 5,104 3,519 4,698 15,939 13,631 15,177 Long-term debt, less debt issuance costs and discounts of $429, $432 and $369 39,379 41,057 38,333 Professional liability risks 1,506 1,497 1,544 Right-of-use operating lease obligations 1,881 1,860 1,863 Income taxes and other liabilities 2,069 2,191 2,041 Stockholders' (deficit) equity: Stockholders' deficit attributable to HCA Healthcare, Inc. (4,394 ) (3,519 ) (2,499 ) Noncontrolling interests 3,156 3,081 3,054 (1,238 ) (438 ) 555 $ 59,536 $ 59,798 $ 59,513 HCA Healthcare, Consolidated Statements of Cash FlowsFor the Six Months Ended June 30, 2025 and 2024Unaudited(Dollars in millions) 2025 2024 Cash flows from operating activities: Net income $ 3,716 $ 3,489 Adjustments to reconcile net income to net cash provided by operating activities: Increase (decrease) in cash from operating assets and liabilities: Accounts receivable 320 (285 ) Inventories and other assets (427 ) (68 ) Accounts payable and accrued expenses (676 ) (459 ) Depreciation and amortization 1,723 1,614 Income taxes 880 (4 ) Losses (gains) on sales of facilities 2 (213 ) Amortization of debt issuance costs and discounts 25 17 Share-based compensation 197 199 Other 101 150 Net cash provided by operating activities 5,861 4,440 Cash flows from investing activities: Purchase of property and equipment (2,167 ) (2,399 ) Acquisition of hospitals and health care entities (326 ) (131 ) Sales of hospitals and health care entities 167 311 Change in investments 41 (14 ) Other 2 (2 ) Net cash used in investing activities (2,283 ) (2,235 ) Cash flows from financing activities: Issuances of long-term debt 5,233 4,483 Net change in short-term borrowings and revolving credit facilities 1,768 (1,030 ) Repayment of long-term debt (5,660 ) (2,269 ) Distributions to noncontrolling interests (394 ) (338 ) Payment of debt issuance costs (57 ) (40 ) Payment of dividends (351 ) (356 ) Repurchase of common stock (5,011 ) (2,547 ) Other (112 ) (212 ) Net cash used in financing activities (4,584 ) (2,309 ) Effect of exchange rate changes on cash and cash equivalents 12 - Change in cash and cash equivalents (994 ) (104 ) Cash and cash equivalents at beginning of period 1,933 935 Cash and cash equivalents at end of period $ 939 $ 831 Interest payments $ 1,074 $ 943 Income tax payments, net $ 146 $ 999 HCA Healthcare, Statistics Second Quarter For the Six Months Ended June 30, 2025 2024 2025 2024 Operations: Number of Hospitals 191 188 191 188 Number of Freestanding Outpatient Surgery Centers* 124 123 124 123 Licensed Beds at End of Period 50,485 49,844 50,485 49,844 Weighted Average Beds in Service 42,858 42,624 42,860 42,594 Reported: Admissions 566,061 554,456 1,142,422 1,115,325 % Change 2.1 % 2.4 % Equivalent Admissions 1,017,994 994,835 2,030,084 1,976,356 % Change 2.3 % 2.7 % Revenue per Equivalent Admission $ 18,276 $ 17,583 $ 18,189 $ 17,624 % Change 3.9 % 3.2 % Inpatient Revenue per Admission $ 19,656 $ 18,814 $ 19,501 $ 18,869 % Change 4.5 % 3.3 % Patient Days 2,675,284 2,662,550 5,511,900 5,444,146 % Change 0.5 % 1.2 % Equivalent Patient Days 4,813,548 4,779,234 9,794,646 9,647,027 % Change 0.7 % 1.5 % Inpatient Surgery Cases 136,122 135,860 269,881 269,258 % Change 0.2 % 0.2 % Outpatient Surgery Cases 258,365 258,967 504,985 511,802 % Change -0.2 % -1.3 % Emergency Room Visits 2,439,763 2,414,960 4,958,479 4,843,874 % Change 1.0 % 2.4 % Outpatient Revenues as a Percentage of Patient Revenues 38.4 % 38.2 % 37.9 % 37.6 % Average Length of Stay (days) 4.726 4.802 4.825 4.881 Occupancy** 72.0 % 71.9 % 74.4 % 73.6 % Same Facility: Admissions 556,544 546,945 1,123,176 1,098,367 % Change 1.8 % 2.3 % Equivalent Admissions 990,092 973,562 1,974,543 1,930,929 % Change 1.7 % 2.3 % Revenue per Equivalent Admission $ 18,110 $ 17,408 $ 18,080 $ 17,456 % Change 4.0 % 3.6 % Inpatient Revenue per Admission $ 19,576 $ 18,741 $ 19,470 $ 18,800 % Change 4.5 % 3.6 % Inpatient Surgery Cases 134,307 134,662 266,330 266,321 % Change -0.3 % 0.0 % Outpatient Surgery Cases 253,006 254,599 495,316 502,037 % Change -0.6 % -1.3 % Emergency Room Visits 2,401,684 2,370,754 4,868,579 4,741,737 % Change 1.3 % 2.7 % * Excludes freestanding endoscopy centers (29 centers at June 30, 2025 and 23 centers at June 30, 2024). ** Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service. HCA Healthcare, Non-GAAP DisclosuresOperating Results Summary(Dollars in millions, except per share amounts) Second Quarter For the Six Months Ended June 30, 2025 2024 2025 2024 Revenues $ 18,605 $ 17,492 $ 36,926 $ 34,831 Net income attributable to HCA Healthcare, Inc. $ 1,653 $ 1,461 $ 3,263 $ 3,052 Losses (gains) on sales of facilities (net of tax) 3 (9 ) 2 (163 ) Net income attributable to HCA Healthcare, Inc., as adjusted (a) 1,656 1,452 3,265 2,889 Depreciation and amortization 863 819 1,723 1,614 Interest expense 568 506 1,115 1,018 Provision for income taxes 524 547 1,026 945 Net income attributable to noncontrolling interests 238 226 453 437 Adjusted EBITDA (a) 3,849 $ 3,550 $ 7,582 $ 6,903 Adjusted EBITDA margin (a) 20.7 % 20.3 % 20.5 % 19.8 % Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. $ 6.83 $ 5.53 $ 13.28 $ 11.47 Losses (gains) on sales of facilities 0.01 (0.03 ) 0.01 (0.61 ) Net income attributable to HCA Healthcare, Inc., as adjusted (a) $ 6.84 $ 5.50 $ 13.29 $ 10.86 Shares used in computing diluted earnings per share (millions) 241.911 264.071 245.654 266.044 __________________________ (a) Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). These non-GAAP financial measures are adjusted to exclude losses (gains) on sales of facilities and losses on retirement of debt. We believe net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams. Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that adjustments, including losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies. Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. HCA Healthcare, Non-GAAP Disclosures2025 Operating Results Forecast(Dollars in millions, except per share amounts) For the Year Ending December 31, 2025 Low High Revenues $ 74,000 $ 76,000 Net income attributable to HCA Healthcare, Inc. (a) $ 6,110 $ 6,480 Depreciation and amortization 3,450 3,495 Interest expense 2,250 2,300 Provision for income taxes 1,930 2,035 Net income attributable to noncontrolling interests 960 990 Adjusted EBITDA (a) (b) $ 14,700 $ 15,300 Diluted earnings per share: Net income attributable to HCA Healthcare, Inc. $ 25.50 $ 27.00 Shares used in computing diluted earnings per share (millions) 240.000 240.000 The Company's forecasted guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks. __________________________ (a) The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. (b) Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams. Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our healthcare facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. View source version on Contacts INVESTOR CONTACT: Frank Morgan615-344-2688 MEDIA CONTACT: Harlow Sumerford615-344-1851 Sign in to access your portfolio
Business Wire
6 minutes ago
- Business Wire
HCA Healthcare Reports Second Quarter 2025 Results
NASHVILLE, Tenn.--(BUSINESS WIRE)-- HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2025. Key second quarter metrics (all percentage changes compare 2Q 2025 to 2Q 2024 unless otherwise noted): 'We are pleased to report strong financial results for the second quarter. They reflected solid revenue growth, improved margins, and better outcomes for our patients. I want to thank our exceptional colleagues for their great work and continuous efforts to improve,' said Sam Hazen, Chief Executive Officer of HCA Healthcare. Revenues in the second quarter of 2025 totaled $18.605 billion, compared to $17.492 billion in the second quarter of 2024. Net income attributable to HCA Healthcare, Inc. totaled $1.653 billion, or $6.83 per diluted share, compared to $1.461 billion, or $5.53 per diluted share, in the second quarter of 2024. Results for the second quarter of 2025 include losses on sales of facilities of $3 million, or $0.01 per diluted share, compared to gains on sales of facilities of $12 million, or $0.03 per diluted share, in the second quarter of 2024. For the second quarter of 2025, Adjusted EBITDA totaled $3.849 billion, compared to $3.550 billion in the second quarter of 2024. Diluted earnings per share, as adjusted, and Adjusted EBITDA are non-GAAP financial measures. A table providing supplemental information on these non-GAAP financial measures and reconciling GAAP measures of financial performance to them is included in this release. Same facility admissions increased 1.8 percent and same facility equivalent admissions increased 1.7 percent in the second quarter of 2025, compared to the prior year period. Same facility emergency room visits increased 1.3 percent in the second quarter of 2025, compared to the prior year period. Same facility inpatient surgeries declined 0.3 percent, and same facility outpatient surgeries declined 0.6 percent in the second quarter of 2025, compared to the same period of 2024. Same facility revenue per equivalent admission increased 4.0 percent in the second quarter of 2025, compared to the second quarter of 2024. Balance Sheet and Cash Flows from Operations As of June 30, 2025, HCA Healthcare, Inc.'s balance sheet reflected cash and cash equivalents of $939 million, total debt of $44.483 billion, and total assets of $59.536 billion. During the second quarter of 2025, capital expenditures totaled $1.176 billion, excluding acquisitions. Cash flows provided by operating activities in the second quarter of 2025 totaled $4.210 billion, compared to $1.971 billion in the second quarter of 2024. During the second quarter of 2025, the Company repurchased 7.031 million shares of its common stock at a cost of $2.505 billion. The Company had $5.753 billion remaining under its repurchase authorization as of June 30, 2025. As of June 30, 2025, the Company had $6.208 billion of availability under its credit facility (after giving effect to letters of credit and amounts reserved to backstop our commercial paper program). Dividend HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share on the Company's common stock. The dividend will be paid on September 30, 2025 to stockholders of record at the close of business on September 16, 2025. The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company's financial condition and results of operations. Future dividends are expected to be funded by cash balances and future cash flows from operations. 2025 Guidance Update Today, the Company is updating its 2025 estimated guidance ranges issued on January 24, 2025. Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 billion. The Company's guidance contains a number of assumptions, including, among others, the Company's current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payer mix, the ongoing impacts of the two major 2024 hurricanes, the impact of current and future health care public policy developments, as well as general business or economic conditions, including inflation, and the impact of trade policies, including tariffs, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets. Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release. The Company's guidance is based on current plans and expectations and are subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company's 'Forward-Looking Statements.' Earnings Conference Call HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company's Investor Relations web page at About the Company As of June 30, 2025, HCA operated 191 hospitals and approximately 2,500 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company's financial guidance for the year ending December 31, 2025, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like 'may,' 'believe,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'initiative' or 'continue.' These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic or business conditions nationally and regionally in our markets, including inflation, and the impact of trade policies, including changes in, or the imposition of, tariffs and/or trade barriers; changes in revenues resulting from declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, pharmaceuticals, supply chain or other expenditures; workforce disruptions; supply and pharmaceutical shortages and disruptions (including as a result of tariffs or geopolitical disruptions); and the impact of potential federal government shutdowns, holds on or cancellations of congressionally authorized spending and interruptions in the distribution of governmental funds, (2) the impact of current and future health care public policy developments and the implementation of new, and possible changes to existing, federal, state or local laws and regulations affecting the health care industry, including the expiration of enhanced premium tax credits ('EPTCs') for individuals eligible to purchase insurance coverage through federal and state-based health insurance marketplaces, changes in the structure and administration of, and funding for, federal and state agencies and programs, and effects of the One Big Beautiful Bill Act ('OBBBA'), (3) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and those that may be required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of OBBBA, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) the ability to achieve operating and financial targets, develop and execute resiliency plans to offset to the extent possible impacts from OBBBA, the scheduled expiration of EPTCs and tariffs, attain expected levels of patient volumes and revenues, and control the costs of providing services, (6) possible reductions or other changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs and state directed payment arrangements, any of which may negatively impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (7) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of actual and potential cybersecurity incidents or security breaches involving us or our vendors and other third parties, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, including Hurricanes Milton and Helene, physical risks from changing global weather patterns or similar events beyond our control on our assets and activities and the communities we serve, (24) changes in U.S. federal, state, or foreign tax laws, interpretations of tax laws by taxing authorities, other standard setting bodies or judicial decisions, (25) the results of our efforts to use technology and resilience initiatives, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to 'Company,' 'HCA' and 'HCA Healthcare' as used throughout this release refer to HCA Healthcare, Inc. and its affiliates. HCA Healthcare, Inc. Condensed Consolidated Comprehensive Income Statements For the Six Months Ended June 30, 2025 and 2024 Unaudited (Dollars in millions, except per share amounts) 2025 2024 Amount Ratio Amount Ratio Revenues $ 36,926 100.0 % $ 34,831 100.0 % Salaries and benefits 16,135 43.7 15,392 44.2 Supplies 5,608 15.2 5,305 15.2 Other operating expenses 7,638 20.7 7,229 20.8 Equity in (earnings) losses of affiliates (37 ) (0.1 ) 2 — Depreciation and amortization 1,723 4.7 1,614 4.6 Interest expense 1,115 3.0 1,018 2.9 Losses (gains) on sales of facilities 2 — (213 ) (0.6 ) 32,184 87.2 30,347 87.1 Income before income taxes 4,742 12.8 4,484 12.9 Provision for income taxes 1,026 2.7 995 2.9 Net income 3,716 10.1 3,489 10.0 Net income attributable to noncontrolling interests 453 1.3 437 1.2 Net income attributable to HCA Healthcare, Inc. $ 3,263 8.8 $ 3,052 8.8 Shares used in computing diluted earnings per share (millions) 245.654 266.044 Comprehensive income attributable to HCA Healthcare, Inc. $ 3,341 $ 3,044 Expand HCA Healthcare, Inc. Operating Statistics 2025 2024 2025 2024 Operations: Number of Hospitals 191 188 191 188 Number of Freestanding Outpatient Surgery Centers* 124 123 124 123 Licensed Beds at End of Period 50,485 49,844 50,485 49,844 Weighted Average Beds in Service 42,858 42,624 42,860 42,594 Reported: Admissions 566,061 554,456 1,142,422 1,115,325 % Change 2.1 % 2.4 % Equivalent Admissions 1,017,994 994,835 2,030,084 1,976,356 % Change 2.3 % 2.7 % Revenue per Equivalent Admission $ 18,276 $ 17,583 $ 18,189 $ 17,624 % Change 3.9 % 3.2 % Inpatient Revenue per Admission $ 19,656 $ 18,814 $ 19,501 $ 18,869 % Change 4.5 % 3.3 % Patient Days 2,675,284 2,662,550 5,511,900 5,444,146 % Change 0.5 % 1.2 % Equivalent Patient Days 4,813,548 4,779,234 9,794,646 9,647,027 % Change 0.7 % 1.5 % Inpatient Surgery Cases 136,122 135,860 269,881 269,258 % Change 0.2 % 0.2 % Outpatient Surgery Cases 258,365 258,967 504,985 511,802 % Change -0.2 % -1.3 % Emergency Room Visits 2,439,763 2,414,960 4,958,479 4,843,874 % Change 1.0 % 2.4 % Outpatient Revenues as a Percentage of Patient Revenues 38.4 % 38.2 % 37.9 % 37.6 % Average Length of Stay (days) 4.726 4.802 4.825 4.881 Occupancy** 72.0 % 71.9 % 74.4 % 73.6 % Same Facility: Admissions 556,544 546,945 1,123,176 1,098,367 % Change 1.8 % 2.3 % Equivalent Admissions 990,092 973,562 1,974,543 1,930,929 % Change 1.7 % 2.3 % Revenue per Equivalent Admission $ 18,110 $ 17,408 $ 18,080 $ 17,456 % Change 4.0 % 3.6 % Inpatient Revenue per Admission $ 19,576 $ 18,741 $ 19,470 $ 18,800 % Change 4.5 % 3.6 % Inpatient Surgery Cases 134,307 134,662 266,330 266,321 % Change -0.3 % 0.0 % Outpatient Surgery Cases 253,006 254,599 495,316 502,037 % Change -0.6 % -1.3 % Emergency Room Visits 2,401,684 2,370,754 4,868,579 4,741,737 % Change 1.3 % 2.7 % * Excludes freestanding endoscopy centers (29 centers at June 30, 2025 and 23 centers at June 30, 2024). Expand __________________________ (a) Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). These non-GAAP financial measures are adjusted to exclude losses (gains) on sales of facilities and losses on retirement of debt. We believe net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams. Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that adjustments, including losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies. Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. Expand The Company's forecasted guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks. __________________________ (a) The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. (b) Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams. Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our healthcare facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. Expand
Business Wire
6 minutes ago
- Business Wire
AMC Entertainment Holdings, Inc. Announces Successful Closing of Comprehensive Refinancing Transactions that Strengthen the Balance Sheet and Position the Company to Prosper from Robust Box Office Rec
LEAWOOD, Kan.--(BUSINESS WIRE)--AMC Entertainment Holdings, Inc. (NYSE: AMC) ('AMC' or the 'Company') today announced the successful completion of a series of previously announced debt refinancing transactions with key creditor groups, including certain holders of its 7.5% Senior Secured Notes due 2029 (the 'Consenting 7.5% Noteholders'), certain holders of Muvico, LLC's 6.00%/8.00% Senior Secured Exchangeable Notes due 2030 (the 'Consenting Exchangeable Noteholders') and certain lenders of AMC's term loans outstanding under its existing credit agreement (the 'Credit Agreement,' and any such consenting lenders, the 'Consenting Term Loan Lenders') that materially strengthen the Company's capital structure and fortify the Company's balance sheet and financial flexibility. The transactions executed in accordance with the Transaction Support Agreement dated July 1, 2025, garnered overwhelming support from creditors, with approximately 90% of Term Loan holders under AMC's Credit Agreement delivering their consent. This support enabled AMC to quickly close the full suite of coordinated transactions, including new capital funding, significant debt reduction, and litigation resolution. Highlights of the now-completed transactions include: New Capital : The Consenting 7.5% Noteholders provided approximately $244 million in new financing and exchanged $590 million of existing notes for $857 million of new Senior Secured Notes due 2029. De-risking of 2026 Maturities : The $244 million of new financing will be used primarily to fully redeem AMC's 5.875% Senior Subordinated Notes and 10.0%/12.0% Cash/PIK Toggle Second Lien Subordinated Secured Notes, both due in 2026, and fund transaction expenses. Debt Reduction : $143 million of AMC's 6.00%/8.00% Senior Secured Exchangeable Notes due 2030, were equitized on July 1, 2025, with the potential to equitize up to a total of $337 million of existing debt, including approximately $194 million of new Senior Secured Exchangeable Notes due 2030 issued to the Consenting Exchangeable Noteholders in exchange for their existing notes. Litigation Resolution : Final dismissal of litigation brought by holders of AMC's 7.5% Senior Secured Notes due 2029. For more information, please refer to the Form 8-K filed by AMC today with the U.S. Securities and Exchange Commission and available on our website at Adam Aron, Chairman and CEO of AMC, commented, 'With the closing of these transformative transactions and the full redemption of our 2026 debt maturities, AMC is unquestionably on offense. Around 90% of our term loan lenders rallied behind this forward-looking plan, a level of support that demonstrates their tremendous confidence in the direction in which AMC is headed.' Aron continued, 'We are especially excited about our dramatic expansion plans for an increased number of premium large format and extra-large screens being offered by AMC and Odeon globally, along with our continued broad deployment of state-of-the-art laser projection technology. AMC Entertainment already offers more premium experiences than any other exhibitor on the planet, and we intend to further increase our lead in this area even that much more. Supported by a wide variety of marketing initiatives that are compelling in the value and messaging that they offer to moviegoers, our offering our guests the best possible experiences in often unique and particularly noteworthy theatres is the secret sauce that is key to our increasing success.' Aron concluded, 'Watch out world, AMC Entertainment is on the way back. With fresh capital secured, near-term debt maturities addressed, and with the overwhelming support of our lenders, we are operating from a clearly improved financial position. Combining our bold balance sheet transactions with the tailwinds of a resurgent box office both domestically and internationally, at AMC we look to the future with optimism, momentum and confidence.' About AMC Entertainment Holdings, Inc. AMC is the largest movie exhibition company in the United States, the largest in Europe and the largest throughout the world with approximately 870 theatres and 9,700 screens across the globe. AMC has propelled innovation in the exhibition industry by: deploying its signature power-recliner seats; delivering enhanced food and beverage choices; generating greater guest engagement through its loyalty and subscription programs, website, and mobile apps; offering premium large format experiences and playing a wide variety of content including the latest Hollywood releases and independent programming. For more information, visit Website Information This press release, along with other news about AMC, is available at We routinely post information that may be important to investors in the Investor Relations section of our website, We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD, and we encourage investors to consult that section of our website regularly for important information about AMC. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document. Investors interested in automatically receiving news and information when posted to our website can also visit to sign up for email alerts. Forward-Looking Statements This communication includes 'forward-looking statements' within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'may,' 'will,' 'forecast,' 'estimate,' 'project,' 'intend,' 'plan,' 'expect,' 'should,' 'believe' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based only on the Company's current beliefs, expectations and assumptions regarding the future of the Company's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions and speak only as of the date on which they are made. Examples of forward-looking statements include statements the Company makes regarding the terms of the transactions, which are highly uncertain; the Company's ability to otherwise refinance, extend, restructure or repay outstanding debt; its current and projected liquidity needs to operate its business and execute its strategy, and related use of cash; its ability to raise capital through equity issuances, asset sales or the incurrence of debt; the Company's expectations regarding its ability to continue as a going concern; retail and credit market conditions; higher cost of capital and borrowing costs; impairments; changes in general economic conditions; the impact of foreign exchange rates on the Company's financial performance; and the Company's inability to implement its business plan or meet or exceed its financial projections. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, and are based on information available at the time the statements are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks, trends, uncertainties and other facts which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. For a detailed discussion of risks, trends and uncertainties facing the Company, see the section entitled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC, and the risks, trends and uncertainties identified in the Company's other public filings. The Company does not intend, and undertakes no duty, to update any information contained herein to reflect future events or circumstances, except as required by applicable law.
